Ascletis Pharma FY26 H1 net loss more than doubled to RMB 319.67 million; total income falls 48.9% to RMB 52.98 million

• Ascletis Pharma posted a net loss of RMB 319.67 million, more than tripling year-on-year, as R&D costs more than doubled to RMB 341.66 million.
• Total income fell 48.9% to RMB 52.98 million, on lower one-off items including government grants and weaker equity investment gains.
• Loss per share widened to RMB 30.74 cents, while administrative expenses dropped 28.9% to RMB 30.8 million.
• Cash and cash equivalents, time deposits and related products totaled about RMB 2.31 billion, supporting operations into 2029.
• ASC30 obesity program began global Phase III dosing; ASC30 diabetes Phase II topline data expected in Q3 2026, Phase III obesity topline in Q3 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309442), on August 31, 2026, and is solely responsible for the information contained therein.